2 cancer drugs from Li Ka-shing-backed Sequencio garner global attention

Two cancer vaccines from Hong Kong-based Sequencio Therapeutics have been selected for presentation at a major US conference, as companies bet on therapies based on ribonucleic acid (RNA) to deliver breakthroughs in cancer treatment. Sequencio, a subsidiary of Li Ka-shing-backed CK Life Sciences, said on Wednesday t…

Opens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.